Commonwealth Equity Services’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$588K Sell
7,829
-3,977
-34% -$314K ﹤0.01% 3078
2025
Q4
$934K Sell
11,806
-1,543
-12% -$116K ﹤0.01% 2637
2025
Q3
$873K Sell
13,349
-593
-4% -$29K ﹤0.01% 2708
2025
Q2
$551K Sell
13,942
-2,456
-15% -$80.4K ﹤0.01% 3064
2025
Q1
$495K Sell
16,398
-5,428
-25% -$178K ﹤0.01% 3028
2024
Q4
$763K Buy
21,826
+373
+2% +$13.9K ﹤0.01% 2614
2024
Q3
$859K Sell
21,453
-1,216
-5% -$56.6K ﹤0.01% 2467
2024
Q2
$1.08M Buy
22,669
+695
+3% +$28.5K ﹤0.01% 2223
2024
Q1
$953K Buy
21,974
+512
+2% +$24.4K ﹤0.01% 2282
2023
Q4
$1.09M Sell
21,462
-8
-0% -$383 ﹤0.01% 2113
2023
Q3
$974K Buy
21,470
+897
+4% +$37K ﹤0.01% 2090
2023
Q2
$844K Sell
20,573
-65
-0.3% -$2.5K ﹤0.01% 2226
2023
Q1
$737 Sell
20,638
-66
-0.3% -$2.48K ﹤0.01% 2250
2022
Q4
$781K Sell
20,704
-543
-3% -$22.8K ﹤0.01% 2126
2022
Q3
$939K Sell
21,247
-2,517
-11% -$106K ﹤0.01% 1944
2022
Q2
$879K Sell
23,764
-2,229
-9% -$84.1K ﹤0.01% 1996
2022
Q1
$962K Sell
25,993
-2,773
-10% -$90.8K ﹤0.01% 2029
2021
Q4
$875K Sell
28,766
-9,352
-25% -$294K ﹤0.01% 2090
2021
Q3
$1.28M Buy
38,118
+12,388
+48% +$467K ﹤0.01% 1741
2021
Q2
$1.03M Buy
25,730
+7,594
+42% +$297K ﹤0.01% 1890
2021
Q1
$815K Sell
18,136
-870
-5% -$48.5K ﹤0.01% 1948
2020
Q4
$1.07M Sell
19,006
-438
-2% -$21.8K ﹤0.01% 1608
2020
Q3
$922K Sell
19,444
-648
-3% -$36K ﹤0.01% 1545
2020
Q2
$1.18M Buy
20,092
+571
+3% +$31.8K ﹤0.01% 1319
2020
Q1
$922K Buy
19,521
+710
+4% +$39.6K ﹤0.01% 1308
2019
Q4
$1.14M Sell
18,811
-791
-4% -$47.1K ﹤0.01% 1345
2019
Q3
$1.17M Buy
19,602
+42
+0.2% +$2.74K 0.01% 1267
2019
Q2
$1.26M Buy
19,560
+374
+2% +$26.4K 0.01% 1208
2019
Q1
$1.56M Buy
19,186
+259
+1% +$16.7K 0.01% 1044
2018
Q4
$1.02M Buy
18,927
+792
+4% +$40.4K 0.01% 1189
2018
Q3
$935K Sell
18,135
-660
-4% -$31K ﹤0.01% 1344
2018
Q2
$783K Sell
18,795
-351
-2% -$15.6K ﹤0.01% 1439
2018
Q1
$843K Buy
19,146
+206
+1% +$10.5K ﹤0.01% 1355
2017
Q4
$953K Buy
18,940
+740
+4% +$40.6K 0.01% 1246
2017
Q3
$923K Sell
18,200
-676
-4% -$35.4K 0.01% 1230
2017
Q2
$960K Buy
18,876
+573
+3% +$26.7K 0.01% 1169
2017
Q1
$736K Buy
18,303
+608
+3% +$27.3K ﹤0.01% 1272
2016
Q4
$846K Sell
17,695
-1,316
-7% -$52.1K 0.01% 1115
2016
Q3
$697K Buy
19,011
+2,594
+16% +$81.2K 0.01% 1191
2016
Q2
$382K Sell
16,417
-16,129
-50% -$520K ﹤0.01% 1519
2016
Q1
$1.32M Buy
32,546
+1,679
+5% +$68.2K 0.01% 827
2015
Q4
$1.91M Buy
30,867
+908
+3% +$49K 0.02% 639
2015
Q3
$1.21M Buy
29,959
+396
+1% +$20.5K 0.01% 808
2015
Q2
$1.7M Sell
29,563
-3,904
-12% -$248K 0.02% 689
2015
Q1
$2.13M Buy
33,467
+6,346
+23% +$431K 0.02% 578
2014
Q4
$1.67M Buy
27,121
+16,645
+159% +$821K 0.02% 645
2014
Q3
$407K Buy
10,476
+1,672
+19% +$59.3K ﹤0.01% 1370
2014
Q2
$303K Buy
8,804
+3,776
+75% +$119K ﹤0.01% 1541
2014
Q1
$217K Buy
+5,028
New +$244K ﹤0.01% 1700
2013
Q4
Sell
-5,350
Closed -$201K 1954
2013
Q3
$201K Buy
+5,350
New +$160K ﹤0.01% 1629

Other funds holding IONS

Commonwealth Equity Services's IONS Position: Q1 2026 in Review

Commonwealth Equity Services reduced its Ionis Pharmaceuticals (IONS) stake by 34% in Q1 2026, selling an estimated $314K and leaving 7,829 shares worth $588K. The position accounts for ﹤0.01% of the portfolio, ranked #3078.

Commonwealth Equity Services first reported a position in IONS in Q3 2013 and has held it in 50 quarters since. The position peaked at $2.13M in Q1 2015. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Commonwealth Equity Services held 7,829 shares of Ionis Pharmaceuticals worth $588K as of Q1 2026.
  • Commonwealth Equity Services sold 3,977 Ionis Pharmaceuticals shares in Q1 2026, an estimated $314K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #3078 holding.
  • Commonwealth Equity Services first reported a position in Ionis Pharmaceuticals in Q3 2013 and has held it in 50 quarters since.
  • Commonwealth Equity Services's Ionis Pharmaceuticals position peaked at $2.13M in Q1 2015.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.